Showing 6501-6510 of 8826 results for "".
- Castle Creek Completes Acquisition of Fibrocell Sciencehttps://practicaldermatology.com/news/castle-creek-completes-acquisition-of-fibrocell-science/2460235/Castle Creek Pharmaceutical Holdings, Inc. completed the acquisition of Fibrocell Science, Inc. Both companies have advanced investigational therapies for the treatment of epidermolysis bullosa (EB) into late-stage clinical research. Prior to the acquisition, Fibrocell initiated a pivot
- Defective Stem Cell Behavior Linked to Psoriasishttps://practicaldermatology.com/news/defective-stem-cell-behavior-linked-to-psoriasis/2460233/Investigators from
- Norfolk Dermatologist Recognized for Increasing Accessibility for Patientshttps://practicaldermatology.com/news/norfolk-dermatologist-recognized-for-increasing-accessibility-for-patients/2460227/Dermatologist Abby Van Voorhees, MD, FAAD, is an American Academy of Dermatology Patient Care Hero for her leadership at the Rapid Access Clinic at the Eastern Virginia Medical School Dermatology Practice in Norfolk, Va. The Eastern Virginia Medical School Dermatology practice allo
- Revance Files BLA for DAXIhttps://practicaldermatology.com/news/revance-files-bla-for-daxi/2460224/Revance Therapeutics, Inc. has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar lines. Under the current Pres
- FDA Accepts NDA for Cassiopea's Clascoterone Cream 1% for Acnehttps://practicaldermatology.com/news/fda-accepts-nda-for-cassiopeas-clascoterone-cream-1-for-acne-1/2460209/The FDA has accepted Cassiopea SpA's New Drug Application (NDA) for clascoterone cream 1% for review. Cassiopea, a specialty pharmaceutical company developing and commercializing prescription drugs with novel mechanisms of action (MOA) to address long-standing and essential dermatological con
- Pinnacle Dermatology Acquires SkinSpeaks Dermatology Clinics in Twin Citieshttps://practicaldermatology.com/news/pinnacle-dermatology-acquires-skinspeaks-dermatology-clinics-in-twin-cities/2460205/Pinnacle Dermatology has acquired SkinSpeaks in the Twin Cities area including locations in Edina, Woodbury, Burnsville, Blaine and Crystal. “We welcome the patients and staff of SkinSpeaks to the Pinnacle Dermatology network of prac
- Cynosure Enters the Muscle Toning Market in Europe, Middle Easthttps://practicaldermatology.com/news/cynosure-enters-the-muscle-toning-market-in-europe-middle-east/2460200/Cynosure, a division of Hologic, is launching StimSure, a non-invasive electromagnetic technology to build and tone muscle in the abdomen, buttocks and thighs, in Europe and the Middle East. CE marked for muscular atrophy, StimSure can be used to strengthen and tighten the abdomina
- Phase 3 Study: Aclaris Therapeutics’ A-101 45% May Help Thwart Common Wartshttps://practicaldermatology.com/news/phase-3-study-aclaris-therapeutics-a-101-45-may-help-thwart-common-warts/2460198/Aclaris Therapeutics, Inc.’s A-101 45% Topical Solution (A-101 45%), an investigational new drug, for the potential treatment of common warts, performed well in its second Phase 3 clinical trial, THWART-1 (WART-301). A-101 45% met the primary and all secondary efficacy endpoints,
- New Indication for Cellfina: Cleared for 5 Years of Benefit for Cellulitehttps://practicaldermatology.com/news/new-indication-for-cellfina-approval-for-5-years-of-benefit-for-cellulite/2460195/The FDA has cleared a new indication statement for Cellfina that shows the benefits of treatment last for five years, an increase from the previous three-year indication. Cellfina from Merz demonstrated five-year improvement in the appearance of cellulite on the buttocks and thighs of adult femal
- FDA Approves Amzeeq Minocycline Foam from Foamixhttps://practicaldermatology.com/news/fda-approves-amzeeq-minocycline-foam-from-foamix/2460194/The FDA has approved Amzeeq (minocycline) topical foam, 4%, from Foamix Pharmaceuticals for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older. Amzeeq, formerly known as FMX101, is the first topical minoc